AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02718144
Drug: Estetrol
RxNorm normalized name: estetrol
DrugBank: Estetrol (DB12235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Estetrol formulated in tablets, in escalating doses, will be investigated in patients with estrogen receptor positive (ER+) locally advanced or metastatic breast cancer.
Trial: NCT01059435
Drug: Romosozumab
RxNorm normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered subcutaneously or intravenously
Trial: NCT00473382
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sterile solution for intravitreal injection.
Trial: NCT00473382
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02999672
Drug: Trastuzumab Emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab emtansine will be administered as Regimen A (2.4 mg/kg qw via IV infusion) or Regimen B (3.6 mg/kg q3w via IV infusion) until unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.
Trial: NCT02476461
Drug: xiapex
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01134055
Drug: pazopanib eye drops
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.
Trial: NCT01967576
Drug: Axitinib (AG-013736)
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg twice a day on a 28-day cycle.
Trial: NCT00464776
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01437566
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle, each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Trial: NCT01437566
Drug: GDC-0941
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive GDC-0941 260 mg (Part II) or 340 mg (Part I) QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Trial: NCT01437566
Drug: GDC-0980
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive GDC-0980 30 mg (Part I) QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Trial: NCT03792906
Drug: Bupivacaine hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg.
Trial: NCT02874989
Drug: Dasatinib + Quercetin
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01967329
Drug: Quadruple
RxNorm normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
DrugBank: Zelpultide alfa (DB18587)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
Trial: NCT04495920
Drug: CGB-S-100
RxNorm normalized name: ethylcellulose (100 MPA S)
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol and choline geranate
Trial: NCT02633709
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole will be administered as an oral 200 mg dose twice daily from Day 1 to Day 8 in Part 3.
Trial: NCT02633709
Drug: Risdiplam
RxNorm normalized name: Risdiplam
DrugBank: Risdiplam (DB15305)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single ascending oral doses of Risdiplam will be administered on Day 1 of Part 1. In Part 2 a single dose of Risdiplam will be once administered under fasted and once under fed conditions. In Part 3 a single dose of Risdiplam will be once administered alone (Period 1) and once concomitantly to itraconazole (Period 2).
Trial: NCT03273088
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single dose of etanercept (25mg/0.5ml prefilled syringe) was administered subcutaneously to healthy subjects.
Trial: NCT02341482
Drug: PF-04958242
RxNorm normalized name: PF-04958242
DrugBank: PF-04958242 (DB11843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT02341482
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT02841332
Drug: F-MISO
RxNorm normalized name: 18F-MISO
DrugBank: Fluoromisonidazole F-18 (DB14830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The fluoro-misonidazole is a positron emission tomography tracer (labeled with Fluorine-18)-specific hypoxia. This compound penetrates into cells where it is reduced by a nitroreductase enzyme. It is rapidly regenerated by reoxidation when the cell is properly oxygenated. This metabolite can accumulate in viable hypoxic cells (necrotic cells that can provide initial reduction reaction of F-MISO).~Moreover, the fixing of this tracer appears to be independent of blood flow. The advantage of this technique is to provide a direct image of hypoxic cells by directly targeting under stress hypoxic.
Trial: NCT02841332
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administration of bevacizumab during 7 cycles of treatment (J1, J15, J30, J45, J60, J120 and J180)
Trial: NCT00394862
Drug: multivitamin
RxNorm normalized name: multivitamin
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02659657
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 (IL-2), 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days)
Trial: NCT04337918
Drug: NORS (Nitric Oxide Releasing Solution)
RxNorm normalized name: Nor-adrenaline
DrugBank: Beclanorsen (DB05606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.
Trial: NCT04337918
Drug: NORS (Nitric Oxide Releasing Solution)
RxNorm normalized name: Nor-adrenaline
DrugBank: Beclanorsen (DB05606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to ten volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.~Any participants enrolled in the Prevention study who meet the criteria for the sub study will roll over into the Treatment Sub-Study but must remain in their randomly assigned group.
Trial: NCT03388164
Drug: Escitalopram + RT2CK17
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
Trial: NCT03388164
Drug: Escitalopram + Placebo
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
Trial: NCT01125696
Drug: Tenofovir/lamivudine/lopinavir-ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tenofovir/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4\<350
Trial: NCT01125696
Drug: Zidovudine/lamivudine/lopinavir-ritonavir
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4\<350
Trial: NCT02858362
Drug: Ezutromid
RxNorm normalized name: Ezutromid
DrugBank: Ezutromid (DB12888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT02359097
Drug: Ferumoxytol
RxNorm normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT02359097
Drug: Gadoteridol
RxNorm normalized name: Gadoteridol
DrugBank: Gadoteridol (DB00597)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00655200
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Trial: NCT00470886
Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan
Trial: NCT01155518
Drug: clomiphene
RxNorm normalized name: Clomiphene
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: thrice a week
Trial: NCT03644472
Drug: nitrate rich beetroot juice
RxNorm normalized name: tamarind juice
DrugBank: Beet (DB10640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
Trial: NCT03644472
Drug: nitrate depleted beetroot juice
RxNorm normalized name: tamarind juice
DrugBank: Beet (DB10640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
Trial: NCT01336218
Drug: fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral tablets, 150mg (3 X 50mg) single dose per period
Trial: NCT01336218
Drug: rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablets, 600mg (2 X 300mg) 8 doses over 8 days
Trial: NCT01280305
Drug: raloxifene
RxNorm normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: raloxifene 60 mg bid
Trial: NCT01891669
Drug: PF-06263507
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined.
Trial: NCT01891669
Drug: PF-06263507
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
Trial: NCT01418365
Drug: Metronidazole + MMX Mesalazine/mesalamine placebo
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine placebo once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine placebo single dose on Day 4 orally
Trial: NCT01418365
Drug: Metronidazole + MMX Mesalazine/mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine 4.8 g once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine 4.8 g single dose on Day 4 orally
Trial: NCT00984646
Drug: Prevascar
RxNorm normalized name: Revascor
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal Prevascar, 5ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Trial: NCT00984646
Drug: Prevascar
RxNorm normalized name: Revascor
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal Prevascar, 50ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Trial: NCT00984646
Drug: Prevascar
RxNorm normalized name: Revascor
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal Prevascar, 250ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Trial: NCT00984646
Drug: Prevascar
RxNorm normalized name: Revascor
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal Prevascar, 1000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Trial: NCT00984646
Drug: Prevascar
RxNorm normalized name: Revascor
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal Prevascar, 25ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Trial: NCT00984646
Drug: Prevascar
RxNorm normalized name: Revascor
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal Prevascar, 125ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Trial: NCT00984646
Drug: Prevascar
RxNorm normalized name: Revascor
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal Prevascar, 500ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Trial: NCT00984646
Drug: Prevascar
RxNorm normalized name: Revascor
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal Prevascar, 2000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Trial: NCT02182726
Drug: MOBEC
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04347174
Drug: Suspension of heat killed (autoclaved) Mycobacterium w
RxNorm normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
DrugBank: Mycobacterium w. Vaccine (DB15798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive either Mycobacterium w in combination with standard care as per hospital practice or standard care alone in COVID-19 as per hospital practice.
Trial: NCT00379691
Drug: phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00631943
Drug: Pregabalin (Lyrica)
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days.
Trial: NCT03214666
Drug: GTB-3550 TriKE® Phase I
DrugBank: GTB-3550 (DB18494)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 1st two patients will be assigned Dose Level 1. The study statistician will assign each new cohort of 2 patients to the most appropriate dose level based on updated toxicity probabilities.~* Dose Level 1 - 5 μg/kg/day~* Dose Level 2 - 10 μg/kg/day~* Dose Level 3 - 25 μg/kg/day~* Dose Level 4 - 50 μg/kg/day~* Dose Level 5 - 100 μg/kg/day~* Dose Level 6 - 150 μg/kg/day~* Dose Level 7 - 200 μg/kg/day
Trial: NCT03214666
Drug: GTB-3550 TriKE® Phase II
DrugBank: GTB-3550 (DB18494)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
Trial: NCT04038411
Drug: PD-1 Antibody, chidamide, lenalidomide and etoposide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
Trial: NCT00150137
Drug: Methimazole
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01754805
Drug: peficitinib
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT00761085
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care for pain management of acute episode of pain
Trial: NCT00761085
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compare to standard of care for pain management of acute episode of pain
Trial: NCT00470275
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03358524
Drug: Vitamin E 400 UNT
RxNorm normalized name: vitamin E 400 UNT
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin-E capsule (alpha tocopherol) 400 IU (once per day)
Trial: NCT02474069
Drug: Secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02296645
Drug: ChloraPrep
RxNorm normalized name: ChloraPrep
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply topically.
Trial: NCT03656380
Drug: Mepolizumab 300 mg
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mepolizumab 300 mg subcutaneous injection
Trial: NCT03656380
Drug: Mepolizumab 100 mg
RxNorm normalized name: mepolizumab 100 MG
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mepolizumab 100 mg subcutaneous injection
Trial: NCT00528593
Drug: epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 1 will receive Procrit once every three weeks, and group 2 will receive Procrit every week.
Trial: NCT00526071
Drug: migalastat HCl
RxNorm normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02743104
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02743104
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02743104
Drug: midazolam and atropine
RxNorm normalized name: pralidoxime and atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02743104
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01551511
Drug: Tetrahydrocannabinol
RxNorm normalized name: Tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
Trial: NCT01995188
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle until disease progression or death, whichever occurs first.
Trial: NCT01995188
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin fixed dose of AUC=6 mg/mL\*min administered by IV infusion on Day 1 of each 21-day dose escalation and expansion cycles. Carboplatin will be administered for a maximum of 6 cycles or until disease progression or unacceptable toxicity, whichever is first.
Trial: NCT02207452
Drug: Salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 5mg nebulised single dose
Trial: NCT02207452
Drug: Ipratropium
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium 500mcg nebulised single dose
Trial: NCT00071006
Drug: AG-013736 (Axitinib)
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients were treated with axitinib at starting dose of 5 mg BID continuous dosing.
Trial: NCT02236936
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin total dose of \>200 mg administered weekly (40 mg/m2/week) or every three weeks (100 mg/m2 every three weeks) according to local standard; not given in combination with cetuximab